Deals
Novartis Says Deals May Be One Way to Heal Troubled Alcon Unit
- CEO Jimenez says deals will help bolster business in near term
- Alcon turnaround should be starting toward end of 2016
Novartis CEO on Alcon Growth Plan, Patents, Pricing
This article is for subscribers only.
Novartis AG is “scanning the market” for acquisitions and licensing opportunities as low valuations create opportunities, especially deals to bolster its ailing eye-care unit Alcon, Chief Executive Officer Joe Jimenez said.
Alcon, which acted as a drag on earnings in recent quarters, has “very good products and projects” that can deliver in the next three to four years, but in the near future it has “a gap here that we’re going need to supplement,” Jimenez said in an interview at the company’s headquarters in Basel, Switzerland.